Latest Oncology News

Five Under 5: Top Oncology Videos for the Week of 2/16

February 23rd 2025

Kristi Rosa

The top 5 videos of the week cover insights in prostate cancer, multiple myeloma, RCC, urothelial carcinoma, and LBCL.

Darolutamide With ADT/Docetaxel Shows Reduced Risk of Death in mHSPC Irrespective of Age

February 23rd 2025

Benjamin Saylor

Darolutamide plus ADT and docetaxel demonstrated efficacy benefits in men with mHSPC regardless of whether they were younger or older than 75 years of age.

The OncFive: Top Oncology Articles for the Week of 2/16

February 22nd 2025

Kristi Rosa

FDA grants priority review to zongertinib in HER2-mutant NSCLC and dordaviprone for recurrent H3K27M+ diffuse glioma, and more from OncLive this week.

Real-World Analysis Reveals Gaps in HRR Testing and PARP Inhibitor Treatment in mCRPC

February 22nd 2025

Darlene Dobkowski, MA

Most patients with mCRPC included in a real-world study did not undergo HRR testing at the time of diagnosis.

Strategic and Safe Lorlatinib Use Is Key to Optimal ALK+ NSCLC Management

February 21st 2025

Ashling Wahner

D. Ross Camidge, MD, PhD, discusses ways that ALK-positive NSCLC management has changed based on 5-year follow-up data with lorlatinib in the CROWN trial.

Latest Oncology Videos

Dr Cortese on the Role of Venetoclax in CLL Immune Synapse Repair

Real-World Data in Myelofibrosis: Bridging the Gap Between Clinical Trials and Practice

Dr Hinchcliff on the Benefits of Chemoimmunotherapy in Endometrial Cancer

Key Updates in the Treatment of ES-SCLC

Ongoing Research to Watch in Ovarian Cancer

Dr Harrison on Investigational JAK Inhibitor–Based Combinations in Myelofibrosis

Advancing Myelofibrosis Treatment: Personalized Strategies with Fedratinib and Ruxolitinib

Dr Falchi on Long-Term Outcomes of Fixed-Duration Epcoritamab Plus R-CHOP in DLBCL

Safety and Efficacy of BAY 2927088 in Patients with HER2-Mutant NSCLC: Expansion Cohort from the Phase I/II SOHO-01 Study

Dr Nathanson on Next Steps for Identifying Novel Resistance Mechanisms in Breast Cancer

Dr Dreyling on Safety Data With ASCT Plus Ibrutinib and Rituximab in Lower-Risk, Younger MCL

Dr Fox on the Design of the TERZO Trial of Duvelisib in R/R Nodal T-Cell Lymphoma

Expert Insights on Recent Advancements in LS-SCLC

Reflections and Future Directions in R/R ALL

Outpatient CAR T Therapy and Expanding Access

FLAURA and FLAURA2: Key Efficacy and Safety Data

Health Care Resource Utilization and Transition of Care

Dr Hernandez-Ilizaliturri on the Implications of Immunologic Changes With Venetoclax in CLL

The Importance of Early Biomarker Testing in Managing Advanced BTC

Guiding Patients Through Advanced BTC Prognosis and Expectations

Novel and Emerging Strategies for HER2+ Breast Cancer With Brain Metastases

Insights From DESTINY-Breast12 Evaluating T-DXd in HER2+ Breast Cancer and Active and Stable Brain Metastases

Dr Vachhani on the Rationale for Evaluating Navtemadlin as a Ruxolitinib Add-On in Myelofibrosis

All Oncology News

TERZO Trial Seeks to Validate Duvelisib as an Effective Targeted Treatment in TFH Nodal T-Cell Lymphoma

February 21st 2025

Courtney Flaherty

Christopher P. Fox, MBChB(Hons), PhD, FRCP, FRCPath, discusses the ongoing evaluation of duvelisib in nodal T-cell lymphoma.

Mevrometostat Plus Enzalutamide Improves rPFS vs Enzalutamide in Metastatic CRPC

February 21st 2025

Megan Hollasch

Pivotal phase 3 trials are ongoing following data from a phase 1 study showing that adding mevrometostat to enzalutamide was safe and efficacious.

Kimberly Stegmaier Named as Pediatric Oncology Chair at Dana-Farber

February 21st 2025

Dana-Farber Cancer Institute

Kimberly Stegmaier, MD, was recently named Chair of Pediatric Oncology at Dana-Farber Cancer Institute.

HyperVIEW X-Ray System Receives FDA Breakthrough Device Designation for Breast Cancer Imaging

February 21st 2025

Kyle Doherty

The HyperVIEW X-ray system has received breakthrough device designation from the FDA for contrast-enhanced imaging for diagnosis of breast cancer.

RZ-001 Earns FDA Fast Track Designation in HCC

February 21st 2025

Courtney Flaherty

RZ-001 has received FDA fast track designation for the treatment of patients with hepatocellular carcinoma.

Odronextamab Shows Efficacy, Safety in R/R DLBCL After Progression Post–CAR T-Cell Therapy

February 21st 2025

Jax DiEugenio

Odronextamab produced durable responses in relapsed/refractory diffuse large B-cell lymphoma after disease progression following CAR T-cell therapy.

Pan-Tumor Approvals Stress the Need for Harmonized Testing and Reporting Strategies

February 21st 2025

Megan Hollasch

Funda Meric-Bernstam, MD, highlights considerations with pan-tumor approvals and where testing and reporting should be improved for clarity/ease.

Frontline Therapy Selection in HCC Hinges on Bleeding Risk and Patient-Specific Factors

February 21st 2025

Jax DiEugenio

Mohammed Najeeb Al Hallak, MD, MS, discusses patient-specific factors to consider during the selection of frontline systemic therapy for HCC.

FDA Grants Fast Track Status to SIGX1094 for Diffuse Gastric Cancer

February 20th 2025

Kristi Rosa

SIGX1094 received fast track designation from the FDA for diffuse gastric cancer.

Key HCC Trial Data Establish the Role of Later-Line Cabozantinib and Raise Further Frontline Questions

February 20th 2025

Ashley Chan

Gentry King, MD, discusses positive and negative outcomes following the phase 3 CELESTIAL and COSMIC-312 trials in patients with hepatocellular carcinoma.

FDA Approval Insights: Mirdametinib for NF1-Associated Plexiform Neurofibromas: With Christopher L. Moertel, MD

February 20th 2025

Christopher L. Moertel, MD

Christopher L. Moertel, MD, discusses the significance of the FDA approval of mirdametinib, based on efficacy and safety data from the phase 2 ReNeu trial.

Epcoritamab Elicits Durable CR Rates, Increases MRD Negativity in Relapsed/Refractory DLBCL

February 20th 2025

Ashley Chan

Julie M. Vose, MD, MBA, discusses the 3-year follow-up data with epcoritamab in patients with relapsed/refractory diffuse large B-cell lymphoma.

Learning to Dance

February 20th 2025

Jill Gilbert, MD

Networking is an underutilized skill that requires practice but can have a high impact on shaping your career path.

UT MD Anderson and Texas Children’s Hospital Announce Joint Venture to End Childhood Cancer

February 20th 2025

MD Anderson Cancer Center

The University of Texas MD Anderson Cancer Center and Texas Children’s Hospital have announced a collaboration dedicated to pediatric cancer care.

Epcoritamab Gains Japanese Approval for R/R Follicular Lymphoma

February 20th 2025

Jax DiEugenio

The Ministry of Health, Labour, and Welfare in Japan has approved epcoritamab for relapsed or refractory follicular lymphoma.

See All News